Marshall Wace’s ImmunityBio IBRX Stock Holding History

Marshall Wace’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$591K	Buy	+77,025	New	+$527K	﹤0.01%	2374
2025 Q4	–	Sell	-254,814	Closed	-$627K	–	3182
2025 Q3	$627K	Buy	+254,814	New	+$656K	﹤0.01%	2142
2025 Q1	–	Sell	-240,311	Closed	-$615K	–	2832
2024 Q4	$615K	Buy	+240,311	New	+$1M	﹤0.01%	1959
2023 Q2	–	Sell	-234,441	Closed	-$427K	–	2672
2023 Q1	$427K	Buy	234,441 +175,133	+295%	+$545K	﹤0.01%	2166
2022 Q4	$301K	Buy	59,308 +7,718	+15%	+$42.4K	﹤0.01%	2567
2022 Q3	$256K	Buy	+51,590	New	+$235K	﹤0.01%	3000
2022 Q2	–	Sell	-153,282	Closed	-$861K	–	3620
2022 Q1	$861K	Sell	153,282 -90,237	-37%	-$554K	﹤0.01%	2518
2021 Q4	$1.48M	Buy	+243,519	New	+$1.83M	﹤0.01%	2240

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace's IBRX Position: Q1 2026 in Review

Marshall Wace opened a new position in ImmunityBio (IBRX) in Q1 2026: 77,025 shares worth $591K. The stake represents ﹤0.01% of the portfolio and ranks #2374 among its holdings. This is a return to the name: Marshall Wace previously reported a position in IBRX as recently as Q3 2025.

Marshall Wace first reported a position in IBRX in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.48M in Q4 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Marshall Wace held 77,025 shares of ImmunityBio worth $591K as of Q1 2026.
ImmunityBio was a new Marshall Wace position in Q1 2026.
ImmunityBio made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2374 holding.
Marshall Wace first reported a position in ImmunityBio in Q4 2021 and has held it in 8 quarters since.
Marshall Wace's ImmunityBio position peaked at $1.48M in Q4 2021.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.